Phar­ma vet Va­le­ria Fan­tin jumps to on­col­o­gy team at Gilead; João Sif­fert out as Abeona looks for an­oth­er CEO

→ News broke on Twit­ter yes­ter­day that Va­le­ria Fan­tin has head­ed to Gilead to be their VP, on­col­o­gy re­search, a field in which CEO Dan O’Day has placed par­tic­u­lar em­pha­sis with the $21 bil­lion ac­qui­si­tion of Im­munomedics.

The well-trav­eled bio­phar­ma ex­ec just com­plet­ed a brief run as CSO at Zai Lab and has al­so been CSO at ORIC Phar­ma­ceu­ti­cals. Fan­tin, who start­ed out in epi­ge­net­ics and ki­nase drug dis­cov­ery at Mer­ck in 2004, then moved to ARI­AD Phar­ma­ceu­ti­cals in 2008, on­ly to quick­ly piv­ot to Agios Phar­ma­ceu­ti­cals not long af­ter its in­cep­tion as a mol­e­c­u­lar on­col­o­gy di­rec­tor. Af­ter Agios, she was VP, tu­mor cell bi­ol­o­gy at Pfiz­er, help­ing de­vel­op Ibrance and dis­cov­er Lor­bre­na.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER